title: Autologous protein solution inhibits MMP-13 production by IL-1β and TNFα-stimulated human articular chondrocytes.
abstract: Catabolic inflammatory cytokines are prevalent in osteoarthritis (OA). The purpose of this study was to evaluate an autologous protein solution (APS) as a potential chondroprotective agent for OA therapy. APS was prepared from platelet-rich plasma (PRP). The APS solution contained both anabolic (bFGF, TGF-β1, TGF-β2, EGF, IGF-1, PDGF-AB, PDGF-BB, and VEGF) and anti-inflammatory (IL-1ra, sTNF-RI, sTNF-RII, IL-4, IL-10, IL-13, and IFNγ) cytokines but low concentrations of catabolic cytokines (IL-1α, IL-1β, TNFα, IL-6, IL-8, IL-17, and IL-18). Human articular chondrocytes were pre-incubated with the antagonists IL-1ra, sTNF-RI, or APS prior to the addition of recombinant human IL-1β or TNFα. Following exposure to inflammatory cytokines, the levels of MMP-13 in the culture medium were evaluated by ELISA. MMP-13 production stimulated in chondrocytes by IL-1β or TNFα was reduced by rhIL-1ra and sTNF-RI to near basal levels. APS was also capable of inhibiting the production of MMP-13 induced by both IL-1β and TNFα. The combination of anabolic and anti-inflammatory cytokines in the APS created from PRP may render this formulation to be a potential candidate for the treatment of inflammation in patients at early stages of OA.
authors: Biomet Biologics, Warsaw, Indiana. jennifer.woodell-may@biomet.com
authors: Jennifer
authors: J
authors: Woodell-May
authors: Andrea
authors: A
authors: Matuska
authors: Megan
authors: M
authors: Oyster
authors: Zachary
authors: Z
authors: Welch
authors: Krista
authors: K
authors: O'Shaughnessey
authors: Jacy
authors: J
authors: Hoeppner
mesh_terms: D001798:Blood Proteins / Q000494:pharmacology*; D002358:Cartilage, Articular / Q000166:cytology; D002478:Cells, Cultured; D019902:Chondrocytes / Q000187:drug effects* / Q000378:metabolism; D004336:Drug Antagonism; D004338:Drug Combinations; D004357:Drug Synergism; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000494:pharmacology; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D007719:Knee Joint / Q000166:cytology; D053509:Matrix Metalloproteinase 13 / Q000378:metabolism*; D053657:Platelet-Rich Plasma / Q000737:chemistry*; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
chemical_list: D001798:Blood Proteins; D004338:Drug Combinations; D053590:Interleukin 1 Receptor Antagonist Protein; D053583:Interleukin-1beta; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; C507079:MMP13 protein, human; D053509:Matrix Metalloproteinase 13